News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Authortity To Spend £18.7 Million To Make Gilead Sciences, Inc. (GILD)'s Sovaldi Available To Most Grave Patients



4/18/2014 7:05:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NHS England is to spend £18.7 million to make new Hepatitis C treatment Sovaldi available to patients with the most advanced disease. Around 500 patients who have acute liver failure, and/or awaiting liver transplantation, are set to benefit from the decision to fund Gilead’s Sovaldi (sofosbuvir). The hepatitis C virus causes inflammation of the liver, affecting its ability to function. Whilst many sufferers naturally clear their infections within six months, others develop chronic hepatitis which is usually life-long without therapy.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES